Search results
Pfizer along witth Eli Lilly and Novo Nordisk, enroute to develop their second generation weight...
CNBC TV18· 5 hours agoPfizer plans to move a reworked, once-a-day version of its weight loss pill, danuglipron, into...
Eli Lilly to buy bowel disease drug developer Morphic for $3.2 bln - ET HealthWorld | Pharma
The Economic Times· 3 days agoLondon: Eli Lilly will acquire Morphic Holding for $3.2 billion in cash, the companies said on...
Pfizer moves forward with once-daily weight loss pill
Clinical Trials Arena· 5 hours agoNovo Nordisk currently dominates the space with its GLP-1 agonist drug Wegovy (semaglutide) which...
Eli Lilly weight loss drug beats Ozempic in head-to-head study - ET HealthWorld | Pharma
The Economic Times· 3 days agoWashington: Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss...
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices - ETPharma
The Economic Times· 12 hours agoWashington: Senator Bernie Sanders on Wednesday expressed confidence that Novo Nordisk can be...
Novo’s once-weekly insulin rejected by FDA
BioPharma Dive· 9 hours agoThe FDA’s decision to turn back the drugmaker’s new insulin product narrows Novo’s lead in the U.S. over Eli Lilly, which has a similar diabetes...
Lilly beefs up bowel disease drug portfolio with $3.2 billion Morphic deal, says report - CNBC TV18
CNBC TV18· 3 days agoLilly counts its IBD drug, Omvoh, among its future growth drivers, besides its blockbuster weight...
Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition
Pharmaceutical Technology· 3 days agoEli Lilly has signed a definitive agreement to acquire Morphic Holding for $3.2bn, expanding its...
Lilly to buy Morphic in $3B bet on inflammation drug
BioPharma Dive· 3 days agoThe deal would hand Lilly an experimental pill that could one day rival Takeda's blockbuster medicine Entyvio as a treatment for inflammatory bowel...
Pfizer thinks it found its obesity pill
BioPharma Dive· 8 hours agoFar behind companies like Novo and Eli Lilly, Pfizer hopes the version of the drug, danuglipron, that it’s chosen to advance can break into the...